GlassScriptPhysician profile
Meena Charan
NPI 1538128418
$2,296.43
in general payments reported to CMS, 2019-2025
23 companies · $436 in 2025
The $436 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $211 · 2021: $392 · 2022: $355 · 2023: $396 · 2024: $329 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $470.56 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $244.28 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $227.78 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $218.88 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $156.95 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $140.10 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $128.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.55 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $112.02 | 2019-2024 | Gardasil 9, Vaqta, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $107.00 | 2019-2023 | Trintellix |
| Paratek Pharmaceuticals, INC. | $76.36 | 2021 | |
| Sanofi Pasteur INC. | $47.93 | 2019-2022 | |
| Exact Sciences Corporation | $45.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vertex Pharmaceuticals Incorporated | $32.84 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.49 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.89 | 2020-2023 | Eliquis |
| Daiichi Sankyo INC. | $24.58 | 2023 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $16.25 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.91 | 2022 | |
| Currax Pharmaceuticals LLC | $13.78 | 2025 | Contrave |
| Biohaven Pharmaceuticals, INC. | $13.42 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.96 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meena Charan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.